Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2007-05-15
2007-05-15
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
Reexamination Certificate
active
10602617
ABSTRACT:
The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity HER2 or EGFR.
REFERENCES:
patent: 3313771 (1967-04-01), Hirth et al.
patent: 5217999 (1993-06-01), Levitzki et al.
patent: 5302606 (1994-04-01), Spada et al.
patent: 5439895 (1995-08-01), Lee et al.
patent: 5656643 (1997-08-01), Spada et al.
patent: 5700823 (1997-12-01), Hirth et al.
patent: 5712395 (1998-01-01), App et al.
patent: 31010/93 (1993-07-01), None
patent: 2069857 (1992-12-01), None
patent: 2086968 (1998-06-01), None
patent: 0 566 226 (1995-11-01), None
patent: 0 537 742 (1996-08-01), None
patent: 0 520 722 (1996-12-01), None
patent: 1191306 (1970-05-01), None
patent: 2240104 (1991-07-01), None
patent: WO 92/02444 (1992-02-01), None
patent: WO 92/20642 (1992-11-01), None
patent: WO 92/21641 (1992-12-01), None
patent: WO 94/26260 (1994-11-01), None
patent: 95/24190 (1995-09-01), None
patent: WO 95/24190 (1995-09-01), None
patent: WO 94/24095 (1997-10-01), None
Ohmichi et al, The Tyrosine Kinase Inhibitor Tyrophostin Blocks the Cellular Actions of Nerve Growth Factor, Biochemistry vol. 32, pp. 4650-4658
U.S. Appl. No. 08/179,570, Hirth et al.
Aaronson, S., “Growth Factors and Cancer,”Science254:1146-1153 (1991).
Affleck et al.,Proc. Annu. Meeting American Associate Cancer Research34:A2298 (1993).
Anafi et al., “Selective Interactions of Transforming and Normal abl Proteins with ATP, Tyrosine-Copolymer Substrates, and Tyrphostins,”J. Bio. Chem. 267:4518-4523 (1992).
Andrews et al. (American Veterinary Medicine Association Panel on Euthanasia), “1993 Report of the AVMA Panel on Euthanasia,”J. American Veterinary Medicine Association202(2):229-249 (1993).
Baselga et al., “Antitumor Effects of Doxorubicin in Combination With Anti-epidermal Growth Factor Receptor Monoclonal Antibodies,”J. of Natl. Cancer Institute85(16):1327-1333 (1993).
Bilder et al., “Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells,”Am. J. Physiol. 260 (Cell Physiol.29):C721-C730 (1991).
Birchall et al., “Compositions for killing internal parasites containing 3-teri-alkyl-4-hydroxy-5-halobenzylidene-malononitriles,”Chemical Abstracts88:535 (1978).
Bryckaert et al., “Inhibition of Platelet-Derived Growth Factor-Induced Mitogenesis and Tyrosine Kinase Activity in Cultured Bone Marrow Fibroblasts by Tyrphostins,”Exp. Cell Research 199:255-261(1992).
Caraglia et al., “Cytosine Arabiniside Increases the Binding of 125I-Labelled Eipdermal Growth Factor and 125I-Transferrin and Enhances the In Vitro Targeting of Human Tumour Cells With Anti- (Growth Factor Receptor) mAB,”Cancer Immunol Immunother37:150-156, (1993).
Carboni et al., “Cyanocarbon Chemistry. XI. Malononitrile Dimer,”J. Am. Chem. Soc. 80:2838-2840 (1958).
Carraway and Cantley, “A Neu Acquaintance for ErbB3 and ErbB4: A Role for Receptor Hereodimerization in Growth Signaling,”Cell78:5-8 (1994).
Carraway et al., “The erbB3 Gene Product Is a Receptor for Heregulin,”J. Biol. Chem. 269:14303-14306 (1994).
Dati et al., “Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells,”Oncogene5:1001-1006 (1990).
Decker and Lohmann-Matthes, “A Quick and Simple Method for the Quantitation of Lactate Dehydrogenase Release in Measurements of Cellular Cytotoxicity and Tumor Necrosis Factor (TNF) Activity,”J. Immunol. Methods115:61 (1988).
Dougall et al., “The Neu-Oncogene: Signal Transduction Pathways, Transformation Mechanisms and Evolving Therapies,”Oncogene9:2109, (1994).
Ferris et al., “Synthesis of Zuinazoline Nucleosides from Ribose and Anthranilonitrile. Application of Phase-Transfer Catalysis in Nucleoside Synthesis,”J. Org. Chem. 442(2):173-178 (1979).
Floege et al., “Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo,”Kidney International43S:47-54 (1993).
Gazit et al., “Tyrphostins, 1. Synthesis and Biological Activity of Protein Tyrosine Kinase Inhibitors,”J. Med. Chem, 32:2344-2352 (1989).
Gazit, et al., “Tyrphostins, 2. Heterocyclic and α-Substituted Benzylidenemalononitrile Tyrphostins as Potent Inhibitors of EGF Receptor and ErbB2
eu Tyrosine Kinases,”J. Med. Chem, 34:1896-1907 (1991).
Gazit et al., “Tyrphostins. 3. Structure-Activity Relationship Studies of a α-Substituted Benzylidenemalononitrile 5-S-Aryltyrphostins”J. Med. Chem. 36:3556-3564 (1993).
Gottardis et al., “Estradiol-Stimulated Growth of MCF-7 Tumors Implanted in Athymic Mice: A Model to Study the Tumoristatic Action of Tamoxifen,”J. Steroid Biochem. 30(1-6):331-314 (1988).
Grantham; F.H., “Role of Hormones in the Growth and Regression of Human Breast Cancer Cells (MCF-7) Transplanted Into Athymic Nude Mice,”J. Natl. Cancer Instit, 67:51-56, (1981).
Hale et al., “Prognostic value of epidermal growth factor receptor expression in cervical carcinoma,”J. Clin. Pathol. 46:149-153 (1993).
Harris et al., “Breast Cancer (First of Three Parts),”New England J. of Medicine327(5):319-328 (1992).
Hoekstra et al., “Differential effects of steurosporine and tyrphostins on receptor tyrosine kinase autophosphorylation and peptide substrate phosphorylation,”Experimental Therapeuticsfrom 84thAnnual Meeting of American Association for Cancer Research, vol. 34, #2455 (1993).
Honegger et al., “Point Mutation at the ATP Binding Site of EGF Receptor Abolishes Protein-Tyrosine Kinase Activity and Alters Cellular Routing,”Cell5:199-209 (1987).
Hudziak et al., “p185HER2Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor,”Molecular and Cellular Biology9:1165-1172 (1989).
Issidorides and Haddadin, “Benzofurazan Oxide. II. Reactions with Enolate Anions,”J. Org. Chem. 31:4067-4068 (1966).
Karameris et al., “Expression of Epidermal Growth Factor (EGF) and Epidermal Growth Factor Receptor (EGFR) in gastric and Colorectal Carcinomas,”Path. Res. Pract. 189:133-137, (1933).
Kaur et al., “Tyrphostin induced growth inhibition: correlation with effect on p210ber-ablautokinase activity in K562 chronic myelogenous leukemia,”Anti-Cancer Drugs, 1994, pp. 213-222, vol. 5, © Rapid Communications of Oxford Ltd.
Koenders et al., “Eipdermal growth factor receptor and prognosis in human breast cancer: a prospective study,”Breast Cancer Reseqrch and Treatment25:21-27 (1993).
Korzeniewski and Callewaert, “An Enzyme-Release Assay for Natural Cytotoxicity,”J. Immunol. Methods64:313 (1983).
Lee and Salemnick, “Purine N-Oxides, LXII. 2,4-Dioxopyrido[2,3-d]pyrimidine N-Oxides,”J. Org. Chem. 40(24):3608-3610 (1975).
Levitzki, A., “Tyrphostins—Potential Antiproliferative Agents and Novel Molecular Tools,”Biochem. Pharm. 40(5):913-918 (1990).
Ley and Seng, “Synthesen unter Verwendung von Benzofuroxan,”Synthesis1975:415-422 (1975).
Lotta, T. et al.,Journal of Computer-Aided Molecular Design6:253-272 (1992).
Lyall et al., “Tyrphostins Inhibit Epidermal Growth Factor (EGF)-Receptor Tyrosine Kinase Activity in Living Cells and EGF-stimulated Cell Proliferation,”J. Bio. Chem. 264:14503-14509 (1989).
Marshall, E., “Search for a Killer: Focus Shifts from Fat to Hormones,”Science259:618-621 (1993).
Mitus and Rosenthal, “Ch. 30—Adult Leukemias,”Textbook of Clinical Oncology, Holleb, Fink and Murphy eds., pp. 410-432.
Mosmann, “Rapid Colorimetric Assays for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assay,”J. Immunol. Methods65:55-63 (19
Chen Hui
Gazit Aviv
Hirth Klaus Peter
Levitzki Alexander
Mann Elaina
Sackey Ebenezer
Sugen Inc.
Yissum Research and Development Company of the Hebrew University
LandOfFree
Method and compositions for inhibiting cell proliferative... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and compositions for inhibiting cell proliferative..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and compositions for inhibiting cell proliferative... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3806560